- Home
- LNKB vs DRTS Comparison
LNKB vs DRTS Comparison
Compare LNKB & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- DRTS
- Stock Information
- Founded
- LNKB 2018
- DRTS 2015
- Country
- LNKB United States
- DRTS Israel
- Employees
- LNKB N/A
- DRTS N/A
- Industry
- LNKB
- DRTS Medical/Dental Instruments
- Sector
- LNKB
- DRTS Health Care
- Exchange
- LNKB Nasdaq
- DRTS Nasdaq
- Market Cap
- LNKB 270.4M
- DRTS 300.2M
- IPO Year
- LNKB N/A
- DRTS N/A
- Fundamental
- Price
- LNKB $7.05
- DRTS $4.17
- Analyst Decision
- LNKB Strong Buy
- DRTS Strong Buy
- Analyst Count
- LNKB 1
- DRTS 1
- Target Price
- LNKB $9.00
- DRTS $9.00
- AVG Volume (30 Days)
- LNKB 60.5K
- DRTS 62.8K
- Earning Date
- LNKB 10-27-2025
- DRTS 11-18-2025
- Dividend Yield
- LNKB 4.26%
- DRTS N/A
- EPS Growth
- LNKB N/A
- DRTS N/A
- EPS
- LNKB 1.01
- DRTS N/A
- Revenue
- LNKB $121,982,000.00
- DRTS N/A
- Revenue This Year
- LNKB $18.26
- DRTS N/A
- Revenue Next Year
- LNKB N/A
- DRTS N/A
- P/E Ratio
- LNKB $6.98
- DRTS N/A
- Revenue Growth
- LNKB 79.01
- DRTS N/A
- 52 Week Low
- LNKB $6.09
- DRTS $2.11
- 52 Week High
- LNKB $7.98
- DRTS $4.69
- Technical
- Relative Strength Index (RSI)
- LNKB 44.84
- DRTS 58.87
- Support Level
- LNKB $6.92
- DRTS $4.07
- Resistance Level
- LNKB $7.25
- DRTS $4.50
- Average True Range (ATR)
- LNKB 0.20
- DRTS 0.20
- MACD
- LNKB -0.03
- DRTS -0.03
- Stochastic Oscillator
- LNKB 26.23
- DRTS 38.20
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.